Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19

Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19 This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital for treatment of severe Covid-19, under the license from Gilead Sciences. https://ift.tt/eA8V8J

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018